Unity Biotechnology Company Insiders
| UBX Stock | USD 0.97 0.02 2.11% |
Unity Biotechnology employs about 16 people. The company is managed by 15 executives with a total tenure of roughly 38 years, averaging almost 2.0 years of service per executive, having 1.07 employees per reported executive. Break down of Unity Biotechnology's management performance can provide insight into the company performance.
Unity Biotechnology Management Team Effectiveness
The company has Return on Asset of (0.3443) % which means that on every $100 spent on assets, it lost $0.3443. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4897) %, meaning that it generated no profit with money invested by stockholders. Unity Biotechnology's management efficiency ratios could be used to measure how well Unity Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Unity Biotechnology Workforce Comparison
Unity Biotechnology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 4,083. Unity Biotechnology adds roughly 16.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Unity Biotechnology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unity Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unity Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Unity Biotechnology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anirvan Ghosh over two weeks ago Disposition of 96797 shares by Anirvan Ghosh of Unity Biotechnology at 1.03 subject to Rule 16b-3 | ||
Anirvan Ghosh over two weeks ago Acquisition by Anirvan Ghosh of 175000 shares of Unity Biotechnology subject to Rule 16b-3 | ||
Nguyen Alexander Hieu over a month ago Acquisition by Nguyen Alexander Hieu of 150000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 | ||
Hashad Yehia over a month ago Insider Trading | ||
Anirvan Ghosh over two months ago Disposition of 642 shares by Anirvan Ghosh of Unity Biotechnology at 2.23 subject to Rule 16b-3 | ||
Anirvan Ghosh over two months ago Acquisition by Anirvan Ghosh of 450000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 | ||
Leonard Keith R over two months ago Acquisition by Leonard Keith R of 25000 shares of Unity Biotechnology subject to Rule 16b-3 | ||
Grossi Federico over three months ago Insider Trading |
Unity Biotechnology Notable Stakeholders
An Unity Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Unity Biotechnology often face trade-offs trying to please all of them. Unity Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Unity Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lynne CPA | CFO Development | Profile | |
| Lynne Sullivan | CFO Development | Profile | |
| Dr AB | CoFounder Director | Profile | |
| Nathan Guz | Vice Operations | Profile | |
| Judith Campisi | Founder | Profile | |
| Daohong MD | Founder | Profile | |
| Anirvan Ghosh | CEO Director | Profile | |
| Jamie MD | Chief Officer | Profile | |
| Alexander Azoy | Chief Officer | Profile | |
| Jan Deursen | Founder | Profile | |
| Alicia MBA | Chief Officer | Profile | |
| Federico MD | Chief Officer | Profile | |
| Przemyslaw Sapieha | Chief Scientist | Profile | |
| Alexander JD | General Secretary | Profile | |
| MPH MD | Head Officer | Profile |
About Unity Biotechnology Management Performance
The success or failure of an entity such as Unity Biotechnology often depends on how effective the management is. Unity Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Unity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Unity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Unity Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.
Please note, the imprecision that can be found in Unity Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Unity Biotechnology. Check Unity Biotechnology's Beneish M Score to see the likelihood of Unity Biotechnology's management manipulating its earnings.
Unity Biotechnology Workforce Analysis
Traditionally, organizations such as Unity Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Unity Biotechnology within its industry.Unity Biotechnology Manpower Efficiency
Return on Unity Biotechnology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 1.7M | |
| Working Capital Per Employee | 937.9K | |
| Working Capital Per Executive | 1M |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.